VNA-318 Reaches the Brain and Alters Neural Activity in First Human Trial

Alzheimer's drug development has long centered on removing amyloid plaques, yet clinical benefits from that strategy have been modest and contested. A growing number of researchers now argue the disease may begin much earlier, when aging brain cells simply lose the ability to generate enough energy to survive. Vandria, a Swiss biotech, is betting on that idea with its lead candidate VNA-318, a drug designed to improve mitochondrial function in neurons.

At the Alzheimer's Association International Conference in London, Vandria presented Phase 1 data showing that after 12 days of dosing, VNA-318 reached the cerebrospinal fluid and produced detectable changes in brain electrical activity measured by quantitative EEG. Specifically, researchers observed a reduction in alpha-band activity, a signal interpreted by UCSF neuroscientist Daniel Mathalon as robust evidence that the drug is pharmacodynamically active in the human brain and may be influencing attention, inhibitory control, and cognitive state.

This early milestone matters because most experimental Alzheimer's drugs that succeed in animals fail to show biological activity once they reach people. Demonstrating both brain penetration and measurable pharmacodynamic engagement in the same Phase 1 readout narrows one of the biggest uncertainties in early-stage neurological drug development.

The mitochondrial angle is scientifically plausible. As people age, mitochondria in neurons become less efficient, reducing ATP output and driving chronic inflammation — a combination increasingly linked to neurodegeneration. Vandria's approach is analogous to restoring power to a city experiencing rolling blackouts rather than demolishing damaged buildings.

Caveats are substantial. Phase 1 trials are primarily safety and pharmacokinetic studies; this is not evidence of cognitive benefit. qEEG signal changes are biomarkers of engagement, not outcomes. Larger, longer trials measuring memory and function are needed. Nonetheless, for a field hungry for mechanistic diversity, these results represent a meaningful, if early, step forward.